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Platelets play an essential role in wound healing by forming
thrombi that plug holes in the walls of damaged blood vessels.
To achieve this, platelets express a diverse array of cell surface
receptors and signaling proteins that induce rapid platelet acti-
vation. In this study we show that two platelet glycoprotein
receptors that signal via an immunoreceptor tyrosine-based
activation motif (ITAM) or an ITAM-like domain, namely the
collagen receptor complex glycoprotein VI (GPVI)-FcR -chain
and the C-type lectin-like receptor 2 (CLEC-2), respectively,
support constitutive (i.e. agonist-independent) signaling in a
cell linemodel using anuclear factor of activatedT-cells (NFAT)
transcriptional reporter assay that can detect low level activa-
tion of phospholipase C (PLC). Constitutive and agonist sig-
naling by both receptors is dependent on Src and Syk family
kinases, and is inhibited by G6b-B, a platelet immunoglobulin
receptor that has two immunoreceptor tyrosine-based inhibi-
tory motifs in its cytosolic tail. Mutation of the conserved
tyrosines in the two immunoreceptor tyrosine-based inhibitory
motifs prevents the inhibitory action of G6b-B. Interestingly,
the inhibitory activity ofG6b-B is independent of the Src homol-
ogy 2 (SH2)-domain containing tyrosine phosphatases, SHP1
and SHP2, and the inositol 5-phosphatase, SHIP. Constitutive
signaling via Src and Syk tyrosine kinases is observed in platelets
and is associated with tyrosine phosphorylation of GPVI-FcR
-chain and CLEC-2. We speculate that inhibition of constitu-
tive signaling through Src and Syk tyrosine kinases by G6b-B
may help to prevent unwanted platelet activation.
TheGPVI-FcR-chain complex is themajor signaling recep-
tor for collagen on platelets and megakaryocytes (1, 2). Cross-
linking of GPVI leads to Src-dependent phosphorylation of a
tandem YXXL sequence on the FcR -chain known as an
immunoreceptor tyrosine-based activation motif (ITAM).4 In
turn, this leads to recruitment and activation of the tyrosine
kinase Syk through its tandem SH2 domains. Syk initiates a
signaling cascade that generates a linker for activation of T
(LAT) cell-dependent signalosome, which mediates activation
of phospholipase C2 (PLC-2) (3, 4). This pathway initiates a
rise in intracellular Ca2 and activation of protein kinase C
leading to platelet aggregation.
CLEC-2 is a 32-kDa C-type lectin-like receptor that func-
tions as a platelet receptor for the snake venom toxin rhodocy-
tin and the lymphatic endothelial marker, podoplanin (5–7).
Like glycoprotein (GP) VI, CLEC-2 signals via sequential acti-
vation of Src and Syk tyrosine kinases leading to activation of
PLC2 (5). The regulation of PLC2 by CLEC-2 is distinct from
that of GPVI in that it uses a single YXXL sequence and is only
partially dependent on the adapter SLP-76 (5, 8).
G6b is a recently identified member of the immunoglobulin
superfamily that exists in several splice variants (9). G6b-B is
the only one of these variants to contain both a transmembrane
region and two immunoreceptor tyrosine-based inhibitory
motifs (ITIMs) that support binding to the two SH2 domain-
containing protein tyrosine phosphatases, SHP1 and SHP2 (9,
10). ITIMs are defined by the consensus sequence (L/I/V/S)-X-
Y-X-X-(L/V) and are commonly found in pairs separated by 15
to 30 amino acid residues (11, 12). The second ITIM inG6b-B is
located 20 amino acids downstream of the first ITIM and
has a slightly different sequence to the above, TXYXXV. G6b-B
is the third ITIM-containing protein to be identified on plate-
lets (10, 13). The other two platelet ITIM receptors are platelet/
endothelial cell adhesion molecule-1 (PECAM-1) and TREM-
like transcript-1 (14–16).
ITIM-containing receptorswere originally identified by their
ability to inhibit signaling by ITAM receptors, as demonstrated
by the selective inhibition of the B-cell receptor when cross-
linked by surface immunoglobulin to Fc receptor IIb
(FcRIIb) (17, 18). However, it is now recognized that ITIM-
containing receptors can also generate stimulatory signals or
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inhibit activation byG protein-coupled receptors. For example,
PECAM-1 has been reported to induce integrin activation in T
cells (19), whereas it causesmild inhibition of platelet activation
by the ITAMand ITAM-like receptors, GPVI and CLEC-2, and
by the G protein-coupled receptor agonist, thrombin (20–23).
The latter action is similar to that of G6b-B, which upon cross-
linking by a specific antibody inhibits activation of platelets by
the GPVI-specific agonist, collagen-related peptide, and the G
protein-coupled receptor agonist ADP (13). In contrast, the
ITIM receptor, TREM-1, which is present on platelet intracel-
lular granules, is translocated to the surface of activated plate-
lets and reinforces platelet activation (16).
In this study we have used a sensitive NFAT reporter assay
that monitors activation of PLC in DT40 B cells to investigate
the effect of G6b-B on signaling by the GPVI-FcR -chain com-
plex and CLEC-2. The NFAT reporter assay monitors weak,
sustained signaling events and gives robust detection of activa-
tion of GPVI by collagen and of CLEC-2 by rhodocytin and
podoplanin (7, 8, 24). The availability of variants of the DT40
cell line deficient in key signaling proteins allows dissection of
the signaling pathways used by the above receptors.
Herewe show that expression of theGPVI-FcR-chain com-
plex and CLEC-2 in DT40 cells leads to the generation of both
constitutive and agonist-induced signals that are inhibited by
G6b-B. This effect is dependent on the two ITIMs in the cyto-
solic tail of G6b-B, although it is independent of the two SH2-
domain containing tyrosine phosphatases, SHP1 and SHP2,
and of the inositol lipid 5-phosphatase, SHIP. Significantly, we
also provide evidence for constitutive signaling through Src and
Syk-dependent kinases in platelets, thereby raising the possibil-
ity that inhibition of this by G6b-B could help to prevent
unwanted platelet activation in the vasculature.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—Anti-human GPVI monoclonal
antibody (mAb) 204-11 has been described previously (25).
Anti-Syk polyclonal Ab (pAb) (26) was kindly provided by J. B.
Bolen (DNAX, CA). Anti-phospho-Syk (Tyr525/526) pAb and
anti-MycmAbwere purchased fromCell SignalingTechnology
(New England Biolabs UK Ltd., Herts, UK). T7-Tag mAb was
purchased from Novagen (Nottingham, UK). Anti-phosphoty-
rosine mAb 4G10, anti-FcR -chain pAb, and normal rabbit
IgG were purchased from Upstate Biotechnology (Milton Key-
nes, UK). Anti-humanCLEC-2mAbwas purchased fromR&D
Systems Inc. (Minneapolis, MN). Anti-PECAM-1 mAb AB468
was from Autogen-Bioclear (Wiltshire, UK). Horseradish per-
oxidase-conjugated donkey anti-rabbit secondary Ab and
enhanced chemiluminescence reagents (ECL) were purchased
from Amersham Biosciences. Mouse IgG1 monoclonal was
purchased from Abcam (Cambridge, UK). Fluorescein isothio-
cyanate-conjugated anti-mouse IgG secondary antibody was
purchased from Sigma. Collagen was obtained from Nycomed
Austria GmbH (Linz, Austria). Rhodocytin was purified from
the venom of Calloselasma rhodostoma (27). The Src kinase
inhibitors used were, PP1, purchased from BioSource Europe
(Nivelles, Belgium); PP2, purchased from Calbiochem (Not-
tingham, UK); and PD0173952, a gift from Pfizer Global
Research and Development (Ann Arbor, MI). The Syk kinase
inhibitor, R406, was a kind gift of Dr. D. Simmons (Cellzome
UK Ltd., Cambridge). FcR -chain “knock-out” mice were bred
as heterozygotes as described (28). 10 mM Pervanadate was
freshly prepared on the day for use by mixing sodium
orthovanadate and hydrogen peroxide in phosphate-buffered
saline to final concentrations 10mM, then left for 5min at room
temperature and kept on ice. Other reagents were from previ-
ously described sources (6, 8, 24).
Constructs—The human pRc/GPVI, pEF6/FcR -chain,
pEF6/CLEC-2, and mutant CLEC-2 (Y7F) expression plasmids
have been previously described (8). The human pcDNA3/-
G6b-B (kindly given by Prof R. D. Campbell, Oxford, UK) has
been described (9) and the human pcDNA3/PECAM-1 (kindly
given by C. D. Buckley, Birmingham, UK) has also been
described (29). The NFAT luciferase reporter containing three
copies of the distal NFAT site from the interleukin-2 promoter
has been described (30).
Making Myc-tagged FcR -Chain—The c-Myc epitope tag
(EQKLISEEDL) was fused at the amino terminus of FcR -chain
by using pEF6/FcR-chain as a template and the primers: forward
(5-GAACAAAAACTCATCTCAGAAGAGGATCTGCTG
GGA GAG CCT CAG CTC-3) and reverse (5-CAG ATC CTC
TTC TGA GAT GAG TTT TTG TTC GGC CGC TGC TTG
TTCAAC-3), and subcloned into pEF6.
Site-directedMutagenesis of G6b-B—Site-directedmutagene-
sis of G6b-B was performed by a QuikChange Site-directed
Mutagenesis Kit (Stratagene, Cambridge, UK). The primers G6b-
B-Y211F-forward (5-CCG AGC CTG CTC TTT GCG GAT
CTG GAC-3) and G6b-B-Y211F-reverse (5-GTC CAG ATC
CGC AAA GAG CAG GCT CGG-3) were used for tyrosine to
phenylalaninemutation inG6b-B (Y211F) usingwild-type human
pcDNA/G6b-Bas a template.TheprimersG6b-B-Y237F-forward
(5-GATGCCTCCACCATCTTTGCAGTTGTAGTTTG-3)
and G6b-B-Y237F-reverse (5-CAA ACT ACA ACT GCA
AAG ATG GTG GAG GCA TC-3) were used for tyrosine to
phenylalanine mutation in G6b-B (Y237F) using wild-type
human pcDNA/G6b-B as a template and they were also used
for tyrosine to phenylalanine mutation in G6b-B (Y211F/
Y237F) usingmutant pcDNA/G6b-B (Y211F) as a template. All
sequences were verified by sequencing.
Cell Culture—Wild-type (WT), Syk-deficient (31), SHP1 and
SHP2 double-deficient (32) (kindly donated by L. Meyaard,
Utrecht, The Netherlands), SHIP-deficient (33) (kindly
donated by D. K. Newman, Milwaukee, WI) DT40 chicken B
cells were grown in RPMI supplemented with 10% fetal bovine
serum, 1% chicken serum, 100 units/ml penicillin, 100 g/ml
streptomycin, 50 M -mercaptoethanol, and 20 mM
glutamine.
Luciferase Assay—The NFAT reporter assay was performed
as described (8, 24). The indicated amount of DNA of each
construct and 15 g of NFAT-luciferase reporter construct
were transfected by electroporation at 350 V and 500microfar-
ads into 2  107 cells of WT, Syk-deficient, and SHP1/SHP2-
deficient DT40 cells. Twenty hours after transfection, live cells
were counted by trypan blue exclusion, and samples divided for
luciferase assay (2  106 cells/ml), flow cytometry (5  105
cells/sample), and Western blotting (1  106 cells/sample).
Collagen was used at 10 g/ml and rhodocytin was used at 50
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nM. Luciferase activity was measured with a Centro LB960
microplate luminometer (Berthold Technologies, Germany).
All results were compared with basal in mock-transfected cells.
Flow Cytometry—Cell surface expression of transfected cells
was analyzed by flow cytometry using 1 g/ml, GPVI mAb,
PECAM-1 mAb, and Myc mAb to detect CLEC-2 and FcR
-chain, T7-Tag mAb to detect G6b-B, or mouse IgG followed
by stainingwith 4g/ml fluorescein isothiocyanate-conjugated
anti-mouse IgG secondary antibody, and assessed on a
FACScalibur (Becton Dickinson, San Jose, CA). Data were ana-
lyzed using CellQuest software.
Human andMouse Platelets—Washed preparations of human
and mouse platelets were prepared as previously described (5, 8).
Platelets were resuspended in a modified Tyrodes-HEPES buffer
at concentrations of 4 108/ml (human) or 2 108/ml (mouse).
Platelets were prewarmed to 37 °C for 5 min and incubated with
inhibitors or solvent controls for up to 10min.
Immunoprecipitation and Western Blotting—Transfected
cells (1 108/ml) were incubated for 30 min in RPMI at 37 °C
before stimulating. After stimulation, transfected cells or plate-
lets were lysed with ice-cold 2 lysis buffer (2% Triton X-100,
2% dodecyl maltoside, 4 mM 4-(2-aminoethyl)benzenesulfonyl
fluoride, 20 g/ml aprotinin, 20 g/ml leupeptin, 2 g/ml pep-
statin, 10 mM sodium orthovanadate, pH 7.5) and insoluble
material was removed by centrifugation. For immunoprecipi-
tation, lysates were precleared with protein A (G)-Sepharose
beads for 30 min at 4 °C and mixed with 2 g of the indicated
antibodies and protein A-Sepharose beads (protein G-Sepha-
rose). Themixturewas rotated for 2 h at 4 °C.Whole cell lysates
or immunoprecipitated lysates were added to 2 Laemmli
sample buffer. Samples were separated by SDS-PAGE on 10 or
4–12% BisTris gels (Invitrogen) and transferred to polyvinyli-
dene difluoridemembrane.Western blotting was carried out as
described previously (24).
Statistical Analysis—Experiments were performed on at
least three occasions and results are shown asmean S.E. with
the exception of the representative Western blots and flow
cytometry histograms. Statistical significance was determined
using Student’s t test.
RESULTS
Constitutive Signaling of GPVI-FcR -Chain in DT40 Cells—
We set out to extend our previous characterization of the
GPVI-FcR -chain signaling pathway in the DT40 B cell line
(24) by testing whether activation of GPVI by collagen is
dependent on its associated FcR -chain. Activation was mon-
itored in the absence and presence of collagen and compared
with mock-transfected cells that had been allowed to settle on
fibronectin using a NFAT-luciferase reporter assay. Adhesion
to fibronectin alone did not induce NFAT activation (not
shown). As anticipated, collagen stimulatedNFATactivation in
DT40 cells expressing both GPVI and an NH2-terminal Myc-
tagged version of FcR -chain, whereas it had no effect when
either subunit was transfected on its own (Fig. 1A and not
shown). The Myc-tagged version of FcR -chain supports
a similar level of activation to that of the wild-type protein (not
shown) and has the advantage that it can be used to monitor
surface expression by flow cytometry, which is not altered by
expression ofGPVI (Fig. 1A,panel ii). In contrast,GPVIwas not
expressed on the surface of DT40 cells in the absence of the FcR
-chain (not shown), as is the case for platelets (34). These
results are consistent with a model in which cross-linking of
GPVI by collagen leads to tyrosine phosphorylation of the FcR
-chain and activation of the tyrosine kinase Syk.
These studies further revealed the unexpected observation
that expression of the Myc-tagged or wild-type FcR -chain
caused a significant increase in luciferase activity that
approached almost 10% of the response to collagen (Fig. 1, A,
panel i and B, panel i). Furthermore, the constitutive signal
from the FcR -chain was not altered by co-expression with
GPVI (Fig. 1A, panel i). Thus the increase in luciferase activity
that was observed in the absence of a stimulatory agonist
reflects signaling by the ITAM-containing protein.
To investigate constitutive signaling in further detail, DT40
cells were transfected with varying concentrations of the FcR
-chain plasmid and the level of NFAT activation monitored.
Increasing levels of transfection of FcR -chain led to a corre-
sponding increase in both NFAT activation (Fig. 1B, panel i)
and FcR -chain expression as shown byWestern blotting (Fig.
1B, panel ii). Furthermore, Western blotting of GPVI-FcR
-chain-transfected cells demonstrated an increase in tyrosine
phosphorylation of a band of 72 kDa that comigrates with Syk,
along with constitutive tyrosine phosphorylation of FcR
-chain (Fig. 1C, panel i). Confirmation that the 72-kDa protein
corresponds to Syk was confirmed using a phosphospecific
antibody (phospho-Syk Tyr525/526) that binds to the activated
tyrosine kinase (not shown). Tyrosine phosphorylation of Syk
and FcR-chainwere inhibited in the presence of the Src family
kinase inhibitor PD0173952 (Fig. 1C, panel i, and not shown).
These results demonstrate that the FcR -chain generates con-
stitutive signals in DT40 cells that lead to tyrosine phosphoryl-
ation of Syk and NFAT activation. Stimulation of GPVI-FcR
-chain-transfected cells with collagen leads to a further
increase in tyrosine phosphorylation of Syk (Fig. 1C, panel ii),
consistent with the activation of Syk by the collagen receptor
complex, as described in earlier studies.
Constitutive Signaling of CLEC-2 in DT40 Cells—The above
studies were extended to CLEC-2, which is a recently identified
platelet glycoprotein receptor that mediates activation through
a single YXXLmotif in its cytosolic tail. CLEC-2 is a receptor for
the snake venom toxin, rhodocytin, and the lymphatic marker
podoplanin. Both agonists induce activation of CLEC-2-trans-
fected DT40 cells, with the response being dependent on the
conserved tyrosine in the cytoplasmic YXXL motif (7, 8).
In the present study, we have confirmed that rhodocytin
stimulates NFAT activation in CLEC-2-transfected DT40 cells,
with the level of response increasing with the level of surface
expression of CLEC-2 (Fig. 2A, panels i and ii). Moreover, as is
the case with the FcR -chain, expression of CLEC-2 was suffi-
cient to increase NFAT activity in the absence of agonist stim-
ulation, with the level of response increasing in parallel with
that of CLEC-2 (Fig. 2A, panels i and ii). The level of constitu-
tive activity approached between 10 and 20% the response to
rhodocytin. Constitutive signaling by CLEC-2 is abolished fol-
lowing mutation of the tyrosine in the CLEC-2 YXXL sequence
to a phenylalanine (Y7F) (Fig. 2B, panel i), as is the case for
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stimulation by rhodocytin (8). Flow cytometry confirmed a
similar level of expression of wild-type and the Y7F mutant of
CLEC-2 in these studies (Fig. 2B, panel ii). These results dem-
onstrate that constitutive and agonist-induced signaling by
CLEC-2 is dependent on the YXXL motif.
Constitutive Signaling by GPVI-FcR -Chain and CLEC-2 Is
Mediated by Src and Syk Tyrosine Kinases—We and others
have previously reported that collagen stimulates phosphoryl-
ation of the FcR -chain ITAM in platelets through the Src
kinases, Fyn and Lyn, leading to recruitment and tyrosine phos-
phorylation of Syk (35–37). Similarly, phosphorylation of
CLEC-2 and Syk by rhodocytin in platelets is mediated through
a Src kinase pathway, although the identity of the Src kinase is
not known (5). Consistent with this, we observed constitutive
and collagen-stimulated tyrosine phosphorylation of Syk in
GPVI-FcR-chain-transfectedDT40 cells (Fig. 1C). In compar-
ison, we have not been able to detect constitutive phosphoryl-
ation of CLEC-2 in our studies, possibly because of a lower level
of expression relative to that of FcR -chain, as shown using a
Myc-tagged version of both proteins (supplemental Fig. S1),
and because the C-type lectin receptor has a single YXXLmotif.
However, we have observed a small increase in constitutive
phosphorylation of Syk in DT40 cells expressing CLEC-2,
which was further increased in the presence of rhodocytin (not
shown).
Experiments were designed to investigate whether NFAT
signaling by the GPVI-FcR -chain complex and CLEC-2 in
transfectedDT40 cells ismediated through Src and Syk kinases.
As shown in Fig. 3A, constitutive and agonist-induced NFAT
activation by both receptors is blocked in the presence of the
Src family kinase inhibitor PD0173952. Furthermore, constitu-
tive and agonist-induced signaling by the two receptors was
also markedly inhibited in the absence of Syk (Fig. 3B and data
not shown). Thus, these results demonstrate that constitutive
and agonist-induced signaling by GPVI-FcR -chain and
CLEC-2 are both dependent on Src family and Syk tyrosine
kinases.
G6b-B Inhibits Constitutive and Agonist-induced Signaling
by GPVI-FcR -Chain and CLEC-2 through Its Two ITIMs—A
series of experiments were undertaken to investigate the possi-
ble regulation of constitutive and agonist-induced signaling
FIGURE 1. Constitutive signaling by the FcR-chain in DT40 cells. A, panel
i, constitutive and collagen-induced signaling in DT40 cells transfected with
plasmids (10g) encodingGPVI and/orMyc-FcR -chain (FcR) was analyzed
using an NFAT-luciferase reporter assay. Cell lysates were analyzed for lucif-
erase activity following incubation withmedia or collagen (10g/ml) for 6 h.
Data are expressed as -fold increase over the basal of mock-transfected cells.
Values are mean S.E. of three independent experiments. Panel ii, GPVI and
FcR surface expressionwasmeasured by flow cytometry following transfec-
tion with 10 g of plasmid of GPVI/Myc-FcR or Myc-FcR only (correspond-
ing to A, panel i) relative to a control IgG. Data are representative of three
experiments.B,constitutivesignalingbytheFcRalone.Paneli,concentration-
dependent constitutive signaling by FcR in DT40 cells. Values are mean 
S.E. of three independent experiments. Panel ii, Western blotting (WB) for FcR
-chain in DT40 cells transfected with increasing amounts of FcR -chain
plasmid. Data are representative of three experiments. C, panel I, constitutive
tyrosine phosphorylation of Syk and FcR. Mock and GPVI-FcR-transfected
DT40 cells were pre-treated with PD0173952 (20 M) for 5 min. Whole cell
lysates were Western blotted for tyrosine phosphorylation using mAb 4G10
and then reprobed for Syk and FcR. Tyrosine phosphorylated bands that
comigrate with Syk and FcR are shown. Panel ii, tyrosine phosphorylation of
Syk in GPVI-FcR-transfected DT40 cells lysates by collagen (30g/ml) is par-
tially inhibited by cotransfection with G6b-B. Cells were stimulated by colla-
gen for 90 s. Experimental conditions were as for panel i. Data are represent-
ative of three experiments.
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through the GPVI-FcR -chain complex and CLEC-2 by the
platelet immunoglobulin receptor G6b-B, which contains two
ITIMs in its cytosolic tail (9, 10). xpression of G6b-B signifi-
cantly inhibited constitutive signaling by both receptors by
more than 60% (Fig. 4,panel i), aswell as inhibiting the response
to collagen and rhodocytin by35 and 60%, respectively (Fig. 4,
panel ii). The greater degree of inhibition of the response to
rhodocytin may reflect the lower
level of expression of CLEC-2 rel-
ative to GPVI-FcR -chain (sup-
plemental Fig. S1). Expression of
G6b-B had no effect on the level of
expression of either CLEC-2 or
GPVI (supplemental Fig. S2). Ex-
pression of G6b-B also partially
inhibited collagen-induced tyrosine
phosphorylation of Syk (Fig. 1C,
panel ii), demonstrating a molecu-
lar basis for its inhibitory action.
These results demonstrate that
G6b-B inhibits constitutive and
agonist-induced signaling induced
byGPVI-FcR-chain andCLEC-2.
G6b-B contains two ITIMs in its
cytosolic tail, which independently
mediate binding to SHP1 and SHP2
following incubation with the pro-
tein-tyrosine phosphatase inhibitor,
pervanadate (9). Mutation of the two
conserved tyrosines at positions 211
and 237 to phenylalanine inhibits
association with the two SH2 do-
main-containing protein-tyrosine ph-
osphatases (9). To investigate whether
eitherorbothof the ITIMsmediate the
inhibitory effect of G6b-B, the Y211F/
Y237Fdoublemutantwas expressed in
DT40cells togetherwiththeGPVI-FcR
-chain complex and CLEC-2. Flow
cytometry was used to confirm sim-
ilar levels of expression of theG6b-B
mutant, GPVI and CLEC-2 in the
transfected cell lines to that in cells
transfected with wild-type G6b-B
and the two YXXL-containing re-
ceptors (supplemental Fig. S2).
Mutation of the two conserved
tyrosines in the G6b-B ITIMs abol-
ished the inhibitory effect of G6b-B
against constitutive and agonist-in-
duced activation of NFAT induced
by GPVI-FcR -chain and CLEC-2
(Fig. 4), whereas mutation of either
of the two tyrosines alone had a par-
tial or neglible effect (not shown). In
line with this, we were able to detect
weak tyrosine phosphorylation of
G6b-B in theDT40-transfected cells
(not shown). These results demonstrate that G6b-B inhibits
constitutive and agonist-induced signaling through the con-
served tyrosines at positions 211 and 237.
The ability of G6b-B to inhibit constitutive and agonist-in-
duced responses mediated through GPVI-FcR -chain and
CLEC-2 was further investigated in the combined absence of
the two SH2 domain-containing tyrosine phosphatases, SHP1
FIGURE 2. Constitutive signaling by CLEC-2 in DT40 cells is dependent on its YXXL motif. A, panel i, con-
stitutive and rhodocytin-induced signaling in DT40 cells transfected with varying amounts of the CLEC-2
plasmid was analyzed by NFAT-luciferase reporter assay. Cells were stimulated with 50 nM rhodocytin for 6 h.
Values aremean S.E. of three independent experiments. Panel ii, CLEC-2 surface expression following trans-
fection with varying amounts of CLEC-2 plasmid was assessed by flow cytometry using anti-Myc tag mAb
relative to a control IgG. Data are representative of three experiments. B, panel i, constitutive and rhodocytin-
induced signaling in cells transfected with wild-type (WT) andmutant (Y7F) CLEC-2. Values are mean S.E. of
three independent experiments. Panel ii, CLEC-2 surface expression (corresponding to panel i) was assessed by
flow cytometry using anti-Myc tagmAb relative to a control IgG. Data are representative of three experiments.
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and SHP2, or in the absence of the 5-inositol phosphatase,
SHIP. Unexpectedly, the absence of the two protein-tyrosine
phosphatases led to an increase in the level of constitutive and
agonist-induced NFAT activation through GPVI-FcR -chain
and CLEC-2, suggesting that both receptors are under dynamic
inhibitory feedback through the two tyrosine phosphatases
(Fig. 5A). Nevertheless, G6b-B was still able to inhibit constitu-
tive and agonist-induced signaling through GPVI-FcR -chain
and CLEC-2 in the absence of SHP-1 and SHP-2 (Fig. 5A).
Indeed, the inhibitory action against rhodocytin was enhanced
in the combined absence of SHP1 and SHP2 (Fig. 5A), although
this may reflect the increased response to rhodocytin that is
observed in the absence of the two protein-tyrosine phospha-
tases. G6b-B also inhibits constitutive and agonist-induced
NFAT activation by GPVI-FcR -chain and CLEC-2 in DT40
cells deficient in the SH2-domain-containing inositol 5-phos-
phatase (SHIP) (Fig. 5B). Indeed the inhibitory action of G6b-B
against CLEC-2 was also enhanced by the absence of the 5-
inositol phosphatase (Fig. 5B), as was the case in the absence of
SHP1 and SHP2.These results demonstrate thatG6b-B inhibits
GPVI and CLEC-2 signaling in DT40 cells by a SHP1/SHP2-
independent and SHIP-independent mechanism.
PECAM-1 Does Not Inhibit Constitutive Signaling in DT40
Cells—A similar set of studies were undertaken to investigate
whether the major platelet ITIM receptor, PECAM-1, also
inhibits constitutive and agonist-induced activation of
NFAT downstream of GPVI-FcR -chain and CLEC-2. As
shown in supplemental Fig. S3A, PECAM-1 had no effect on
constitutive or agonist-induced activation of either receptor in
DT40 cells, possibly because of a low level of expression (sup-
plemental Fig. S3B).
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FIGURE 3. Constitutive and agonist-induced signaling by GPVI-FcR
-chain and CLEC-2 is dependent on Src and Syk tyrosine kinases. Con-
stitutive and agonist-induced signaling in wild-type (WT) and Syk-deficient
DT40cells transfectedwithGPVI-FcR-chainorCLEC-2was analyzedusingan
NFAT-luciferase reporter assay. Cell lysates were analyzed for luciferase activ-
ity following agonist stimulation for 6 h. A, WT DT40 cells were either mock-
transfected or transfectedwith (panel i) GPVI-FcR -chain (10g of each plas-
mid) or (panel ii) CLEC-2 (10g) and stimulated with 10g/ml collagen or 50
nM rhodocytin in the presence and absence of the Src kinase inhibitor,
PD0173952 (20M). B, basal signaling inWT or Syk-deficient DT40 cells trans-
fectedwithmockor transfectedwith (panel i) GPVI-FcR-chain (10gof each
plasmid) or (panel ii) CLEC-2 (10 g) and incubated for 6 h to monitor the
degreeof constitutive signaling. Values aremean S.E. of three independent
experiments.
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FIGURE 4. The novel platelet ITIM transmembrane proteinG6b-B inhibits
constitutive and agonist-induced signaling through GPVI and CLEC-2.
The effect of the wild-type (WT) and double ITIM-mutant transmembrane
protein G6b-B (Y211F/Y237F) on (panel i) constitutive and (panel ii) agonist-
induced signaling by GPVI-FcR -chain and CLEC-2 in transfected (10 g of
each plasmid) DT40 cells, measured using an NFAT-luciferase reporter assay.
Cells were stimulated with 10 g/ml collagen or 50 nM rhodocytin as appro-
priate. The double ITIM mutant contained inactivating point mutations (Y/F)
at tyrosines 211 and 237. The results are mean  S.E. of between 4 and 7
independent experiments. Statistical significancewas indicated by Student’s
t test. *, p  0.05; and **, p  0.01 compared with the GPVI-FcR -chain or
CLEC-2-transfected samples.
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FIGURE 5. The inhibitory effect of G6b-B is independent of SHP1, SHP2,
and SHIP.Constitutive and agonist-induced signaling in SHP1/SHP2 double-
deficient (A) and SHIP-deficient DT40 cells (B) transfected with GPVI-FcR
-chain, CLEC-2, and G6b-B was analyzed using a NFAT-luciferase reporter
assay. Cells were stimulated with 10 g/ml collagen or 50 nM rhodocytin for
6 h. *, p  0.05 relative to response in the absence of G6b-B. Values are
mean S.E. of three independent experiments.
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Src and Syk Kinase-dependent Constitutive Signaling in
Platelets—Experiments were designed to investigate whether
there is evidence for constitutive signaling through Src and
Syk kinases in platelets. In this context, it is important to
emphasize that platelets express several classes of receptor
that signal through Src and Syk tyrosine kinases, including
the major platelet integrin, IIb3, and the GPIb-IX-V com-
plex, the levels of which are over 1 order of magnitude
greater than that of GPVI-FcR -chain and CLEC-2.
We first asked the question as to whether the tyrosine
phosphorylation that is seen in the absence of agonist stim-
ulation in platelets is regulated by Src or Syk tyrosine
kinases. Western blotting for phosphotyrosine using the
monoclonal antibody 4G10 reveals the presence of a broad
band of proteins in non-stimulated platelets of between 50
and 60 kDa (Fig. 6A), which covers the region of migration of
Src family kinases. This region includes Src kinases, which
are constitutively phosphorylated in resting platelets by the
Src kinase-regulatory protein, Csk, at an inhibitory site that
promotes intramolecular binding to the SH2 domain. In
addition, several other proteins, which have been shown to
be constitutively phosphorylated in nonstimulated platelets,
migrate in this region, including Dok-2 (38). Additional
phosphorylation bands that lie outside of this region can also
be seen in non-stimulated platelets in longer exposures, as
illustrated in Fig. 6A. Tyrosine phosphorylation of the
majority of these bands is markedly inhibited in the presence
of the Src family kinase inhibitors, PP1 and PP2, and the Syk
family kinase inhibitor, R406 (39), with the exception of the
broad band of proteins that runs at 50–60 kDa, which is only
partially reduced (Fig. 6A and not shown). The residual
phosphorylation that is seen in this region is likely to reflect
phosphorylation of Src kinases on their inhibitory site by
Csk. Significantly, Csk is not known to be regulated down-
stream of Src and Syk kinases. The reduction in phosphoryl-
ation in this region is presumably due to loss of phosphoryl-
ation of proteins such as Dok-2, as discussed above. The
similar pattern of reduction in tyrosine phosphorylation that
is induced by R406 to that of PP2 cannot be due to direct
inhibition of Src kinases, as R406 does not inhibit collagen-
stimulated tyrosine phosphorylation of the FcR -chain,5
which is mediated through Src kinase activation. These
results demonstrate that constitutive signaling by Src and
Syk family kinases underlies tyrosine phosphorylation of the
majority of proteins in non-stimulated platelets, thereby
providing evidence of constitutive signaling by Src and Syk
kinases.
We used the protein-tyrosine phosphatase inhibitor, per-
vanadate, to further investigate the contribution of Src and
Syk family kinases to constitutive tyrosine phosphorylation
in human and mouse platelets, on the grounds that this
would potentiate protein tyrosine phosphorylation by con-
stitutively active tyrosine kinases. Results are shown for
mouse platelets (Fig. 6B), with similar observations made for
human platelets (not shown). As previously reported (40–
42), pervanadate induces a marked increase in tyrosine phos-
phorylation of a large number of proteins in platelets (Fig.
6B). Strikingly, protein tyrosine phosphorylation induced by
pervanadate was dramatically inhibited in the presence of
the Src kinase inhibitor, PP2, confirming that Src family
kinases are the major family of kinases that contribute to
constitutive tyrosine phosphorylation in platelets. A small
number of tyrosine-phosphorylated proteins are seen in lon-
ger exposures of pervanadate-treated platelets in the pres-
ence of PP2, including a band of 72 kDa (Fig. 6B) that was
identified as Syk by immunoprecipitation of the kinase and
Western blotting for phosphotyrosine (Fig. 6B). These data
confirm that Src kinases are constitutively active in non-
stimulated platelets and demonstrate that they underlie the
major increase in tyrosine phosphorylation that is induced in
the presence of protein-tyrosine phosphatase inhibition.
Further experiments were designed to investigate the possi-
ble dependence of constitutive signaling through Src and Syk
family kinases on the GPVI-FcR -chain complex. For these
experiments, Sykwas immunoprecipitated from resting human
platelets and Western blotted for phosphotyrosine in the
absence and presence of the Src family kinase inhibitor,
PD0173952. The results in Fig. 6C demonstrate association of
constitutively tyrosine-phosphorylated Syk and constitutively
tyrosine-phosphorylated FcR -chain, which is dramatically
5 J. C. Spalton and S. P. Watson, unpublished data.
W
T
KO W
T
KO W
T
KO
(D)
PP
2
R
40
6
D
M
SO
175
80
58
46
30
25
16.5
6.5
WB: pTyr
14
6.5
66.5
MW
(kDa)PP
1
PDD
M
SO
Syk
MW
(kDa)
WB: pTyr
WB: Syk
D
M
SO
IgG
(C)
175
80
25
WB: pTyr
WB: CLEC-2
IP: CLEC-2
rhodocytin
PP2
- - +     +
- +      +     -
IP:
58
46
30
6.5
58
MW
(kDa)- - +    +    +    +
- - - - +    +PP2
PV
WB: pTyr
WB: Syk
FIGURE 6. Constitutive tyrosine phosphorylation of FcR -chain and Syk
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Whole cell lysates were probed for phosphotyrosine (pTyr). B, wild-type (WT)
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were incubated at 37 °C with the Src kinase inhibitors PP1 (10 M) or
PD0173952 (10 M) for 5 min. Cell lysates were immunoprecipitated with
anti-SykAbor an IgGandprobed for Tyr(P). Subsequently, theywere stripped
and reprobed for Syk.D, humanwashed plateletswere stimulatedwith 30 nM
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Western blot.
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reduced in the presence of the Src kinase inhibitor PD0173952.
On the other hand, treatment of FcR -chain-deficient mouse
platelets with pervanadate revealed that constitutive tyrosine
phosphorylation in mouse platelets is minimally altered in
platelets deficient in the ITAM-containing protein (Fig. 6B),
demonstrating that the GPVI-FcR -chain complex makes a
relatively minor contribution to the overall level of tyrosine
phosphorylation.
Constitutive phosphorylation of CLEC-2 is observed in
human platelets and is reduced in the presence of the Src kinase
inhibitor, PP2 (Fig. 6D). The contribution of CLEC-2 to consti-
tutive tyrosine phosphorylation in mouse platelets cannot be
assessed, as mice lacking the C-type lectin receptor have not
been made.
DISCUSSION
The present study demonstrates that the GPVI-FcR
-chain complex and CLEC-2 generate constitutive signals
in transfected DT40 cells leading to NFAT activation with
the degree of signaling corresponding to the level of expres-
sion. Furthermore, the dependence on Src and Syk family
kinases provides strong evidence that constitutive signaling
by both receptors is mediated through the same pathway as
used by agonists to mediate activation. In line with this, con-
stitutive signaling by CLEC-2 is inhibited by mutation of the
conserved tyrosine in the YXXL sequence in its cytosolic tail.
Furthermore, the response to the GPVI-FcR -chain com-
plex is mediated by FcR -chain, and is independent of GPVI,
consistent with it being generated through the tandemYXXL
sequence of the FcR -chain.
Constitutive and agonist-induced signaling through
GPVI-FcR -chain and CLEC-2 is reduced by co-expression
of the ITIM-containing platelet protein, G6b-B (9). The
inhibitory effect of G6b-B is dependent on the conserved
tyrosines in its two ITIMs, as shown by abolition of the
inhibitory response upon mutation of the ITIM tyrosines to
phenylalanine. However, unexpectedly, this inhibitory effect
is retained in DT40 cells in the combined absence of the SH2
domain-containing tyrosine phosphatases, SHP1 and SHP2,
which have been shown to bind to G6b-B (9, 10). The inhib-
itory effect of G6b-B is also retained in the absence of the
SH2 domain-containing inositol phosphatase, SHIP, which
has been shown to inhibit B cell receptor signaling through
association with the FcRIIb ITIM (43, 44). An alternative
pathway of inhibition could be through recruitment of the
SH2 domain-containing inhibitor of Src kinases, Csk, to the
two ITIMs in G6b-B. Such a mechanism has been proposed
to underlie the inhibition of FcRI signaling by the ITIM-
containing transmembrane protein, LAIR-1, in rat Rbl mast
cells (45). However, we were unable to demonstrate associ-
ation of Csk with G6b-B in transfected DT40 cells (not
shown), possibly because of the low level of constitutive
phosphorylation of the ITIM-containing protein. Access to
Csk-deficient DT40 cells is required to directly test the role
of the Src kinase regulatory protein in mediating the inhibi-
tory effect of G6b-B. It is also possible that the inhibitory
effect of G6b-B is mediated by association with several pro-
teins, including a combination of SHP1, SHP2, SHIP, and
Csk, such that loss of any one is compensated by expression
of the others. Such a mechanism would explain why G6b-B is
still able to mediate inhibition in DT40 cells deficient in
SHP1 and SHP2, which have both been shown to bind to its
cytosolic ITIMs. Interestingly, we observed a small reduc-
tion in tyrosine phosphorylation of Syk by G6b-B in DT40
cells stimulated by collagen, suggesting that this underlies
the inhibitory effect of the ITIM-containing protein.
The observation that the FcR -chain and CLEC-2 gener-
ate constitutive signals is in line with reports that ITAM
receptors generate weak, constitutive signals in other hema-
topoietic cells. For example, in mouse thymocytes and
peripheral T cells, there is limited constitutive phosphoryl-
ation of TCR chains leading to association with the Syk-
related tyrosine kinase ZAP-70 (46, 47). This gives rise to
constitutive signaling in resting mouse thymocyte and Jurkat
T cell lines, as shown by suppression of RAG gene expression
via extracellular signal-regulated kinase (ERK) and Abl
kinases, and prevention of further recombination of T cell
receptor genes (48). The B cell antigen receptor also signals
independently of ligand engagement and this provides func-
tionally relevant signals in immature B lymphocytes (49) and
in diffuse large B-cell lymphoma (50). Significantly, this con-
stitutive signaling is mediated through the B cell receptor
ITAMs (51, 52). Thus, constitutive signaling appears to be a
common feature of YXXL-containing receptors.
Evidence of constitutive signaling through Src and Syk
tyrosine kinases in platelets has been demonstrated in the
present study in association with a low level of tyrosine phos-
phorylation of the FcR -chain and CLEC-2. Studies in mice
deficient in the FcR -chain demonstrate that the GPVI
receptor complex makes only a minimal contribution to this
phosphorylation, most likely because of the association of
Src kinases with other surface receptors, including the
IIb3 complex that is expressed at over 20 times the level of
GPVI.
The demonstration of constitutive signaling via Src and
Syk kinases in platelets emphasizes the need for inhibitory
signals to oppose activation occurring in healthy vessels. We
speculate that this function may be mediated, at least in part,
by the ITIM receptor, G6b-B, which is markedly phospho-
rylated in resting platelets (10). The ligand for G6b-B is not
known, but if this is expressed on platelets, it is possible that
this may account for the high level of constitutive phospho-
rylation of G6b-B through a cis-interaction.
A similar function to that of G6b-B may be mediated in
platelets by the ITIM-containing receptor, PECAM-1. This
is in line with studies that have reported inhibition of ago-
nist-induced platelet activation by the immunoglobulin
receptor (21–23). However, unexpectedly, we were unable to
observe inhibition of constitutive and agonist-induced sig-
naling by PECAM-1 in the DT40 cell line, possibly because of
too low a level of expression.
In summary, the present study reports that both FcR -chain
and CLEC-2 generate weak, sustained constitutive signals that
are inhibited by co-expression with G6b-B. We speculate that
this could represent an important physiological role of G6b-B
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and other platelet ITIM proteins in helping to prevent platelet
activation in vivo.
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